---
figid: PMC3562627__jgo-04-01-072-f2
figlink: /pmc/articles/PMC3562627/figure/f2/
number: Figure 2
caption: A. Inactivation of EGFR by anti-EGFR drugs does not inhibit the activation
  of RAS-MAPK pathway due to BRAF oncogene mutation, shown in red, which causes uncontrolled
  cellular proliferation, migration, and survival etc; B. Combination of cetuximab/panitumumab
  and BRAF inhibitor i.e., Vemurafenib PLX4030 inhibit the downstream signaling cascade,
  oncogenic proliferation and survival in BRAF mutated cells
pmcid: PMC3562627
papertitle: The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and
  BRAF inhibitors in BRAF mutated colorectal cancer.
reftext: Shan Muhammad, et al. J Gastrointest Oncol. 2013 Mar;4(1):72-81.
pmc_ranked_result_index: '26206'
pathway_score: 0.9209554
filename: jgo-04-01-072-f2.jpg
figtitle: EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors
  in BRAF mutated colorectal cancer
year: '2013'
organisms: Homo sapiens
ndex: eb592217-df0c-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3562627__jgo-04-01-072-f2.html
  '@type': Dataset
  description: A. Inactivation of EGFR by anti-EGFR drugs does not inhibit the activation
    of RAS-MAPK pathway due to BRAF oncogene mutation, shown in red, which causes
    uncontrolled cellular proliferation, migration, and survival etc; B. Combination
    of cetuximab/panitumumab and BRAF inhibitor i.e., Vemurafenib PLX4030 inhibit
    the downstream signaling cascade, oncogenic proliferation and survival in BRAF
    mutated cells
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K2
  - MAPK12
  - KRAS
  - MAP2K1
  - MAPK13
  - EGFR
  - MAPK14
  - MAPK10
  - MAPK3
  - MAPK1
  - BRAF
  - MAPK9
  - MAPK11
  - MAPK8
genes:
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK/MAPK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: ERK/MAPK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
chemicals: []
diseases: []
---
